Heat Biologics, Inc. (HTBX) News
Filter HTBX News Items
HTBX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HTBX News Highlights
- HTBX's 30 day story count now stands at 10.
- Over the past 12 days, the trend for HTBX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about HTBX are HHS and BASE.
Latest HTBX News From Around the Web
Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.
Morrisville firm targeting biothreats will leave the Nasdaq; new subsidiary scores $81M contractThe future subsidiary of a Triangle drugmaker has scored a federal contract potentially worth up to roughly $81 million. Meanwhile, the company is preparing to leave the Nasdaq for another stock exchange. |
Heat Biologics to move to NYSE from NasdaqHeat Biologics (HTBX) said it plans to change its listing to the NYSE American stock exchange from from the Nasdaq Capital Market.Heat expects to begin trading on NYSE under its |
Heat Biologics Announces Planned Transfer to the NYSE AmericanDURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it plans to change its listing from the Nasdaq Capital Market to the NYSE American stock exchange. “We are pleased to announce our listing on the NYSE American, a global leader in listings for a range of sectors, including life sciences and technology,” said Jeff |
Heat Biologics rises 10% as Elusys finalizes HHS contract for anthrax antitoxin AnthimElusys Therapeutics, which is being acquired by Heat Biologics < |
Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax TreatmentElusys Therapeutics Inc, the merger partner for Heat Biologics Inc (NASDAQ: HTBX), has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin. The contract for ANTHIM consists of a base period of performance, valued at $50 million, which is fulfilled. The contract includes options valued at up to $31 million. If all optio |
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human ServicesCompleted first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S. government’s strategy to maintain sufficient quantities of anthrax anti-toxin to effectively respond to an anthrax emergency PARSIPPANY, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Elusys Therapeutics, Inc. (Elusys) announced today that it has finalized a contract with the Office of the Assistant Secretary |
Heat Biologics (HTBX) Investor Presentation - SlideshowNo summary available. |
HTBX: RapidVax Unveiled; Elusys AcquisitionBy John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Since Our Last Update Since our last update, Heat Biologics, Inc. (NASDAQ:HTBX) has announced several major developments including the unveiling of Heat’s RapidVax novel cellular vaccine platform, a planned acquisition of Elusys Therapeutics, and new PTX-35 preclinical data in organ transplantation. Heat also looks forward |
Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110Heat Biologics Inc (NASDAQ: HTBX ) announced promising preclinical data regarding PTX-35 . The data has been accepted for publication in the American Journal of Transplantation. A single dose of the preclinical version of PTX-35 (mPTX-35) expanded regulatory T cells (Tregs) and significantly improved disease and graft survival outcomes. Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted Full story available on Benzinga.com |
Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclinical data regarding PTX-35 has been accepted for publication in the American Journal of Transplantation and is available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.16940 . Key Findings : A single dose of the preclinical version of PTX-35 (mPTX-35), was able to expand regulatory T cells (Tregs) and significantly improve disease and graft survival outcomes. Chemically induced pancreatic failure (a model for type-1 diabetes) could be partially reversed when mice were transplanted with beta-cell islet allografts and treated with... |